3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Tacrolimus
4
Epoetin Alfa
4
Busulfan
4
fludarabine
3
Darbepoetin alfa
3
Bortezomib
3
fludarabine phosphate
2
dacetuzumab
2
Rituximab
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Lenalidomide
2
Early Intervention, Educational
2
Dexamethasone
2
Antilymphocyte Serum
2
Alemtuzumab
2
venetoclax
1
trametinib
1
ruxolitinib
1
plerixafor
1
isatuximab
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ethanolamine oleate
1
dabrafenib
1
Vorinostat
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
ficlatuzumab
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled